Tenderwize
Wróć do wyszukiwania

Open House Originale Contract for Sofosbuvir/Velpatasvir/Voxilaprevir

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 370 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-21 - Sofosbuvir, Velpatasvir, Voxilaprevir (Wirkstoffkombination)

62/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

62 / 100

Złożoność

58 / 100

Czynniki ryzyka

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Only pharmaceutical undertakings for the relevant medicines, with the required seat and marketing authorisation, may pa...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply/rebate contract for pharmaceutical products concerning the combination Sofosbuvir, Velpatasvir, Voxilaprevir.
  • Nationwide performance in Germany.
Pokaż pełne podsumowanie

Open House-style pharmaceutical supply arrangement by Techniker Krankenkasse for the fixed combination Sofosbuvir/Velpatasvir/Voxilaprevir. The notice states there is no exclusivity, no individual negotiation, and contracts can be joined at any time during the term. The contract term runs from 2025-09-01 to 2027-08-31 at the latest, with earlier automatic end if patent/market exclusivity expires. No contract value is stated. Participation is restricted to pharmaceutical companies meeting the stated legal and self-declaration requirements, and submission is not via the portal but by email or post.

Ryzyka

Offers/contracts cannot be submitted through the portal; they must be sent by email with qualified electronic signature...

Only pharmaceutical undertakings for the relevant medicines, with the required seat and marketing authorisation, may pa...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of § 4 Abs. 18 AMG for the relevant medicines.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicines or otherwise be entitled to place them on the market in its own name.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open House Originale Contract for Sofosbuvir/Velpatasvir/Voxilaprevir

Single lot covering rebate contracts for the medicinal product combination Sofosbuvir, Velpatasvir, Voxilaprevir. Scope is nationwide in Germany. The notice says the arrangement is open to all suitable pharmaceutical companies, with uniform conditions, no exclusivity, and no individual negotiations. The lot information comes from structured data and the XML notice.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Aug 2025 - Aug 2027

Kategoria

Pharmaceutical products

Termin

Deadline Aug 30, 2027

Szczegóły zamówienia

Data publikacji
22 Jul 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
481017-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3